Sareum Holdings stock | Price, analyst rating, price target & growth

Sareum Holdings

AIM:SAR

£ 0,16

£0,00 (0,00%)

0,16 £

£0,00 (0,00%)

End-of-day quote: 04/08/2026

Sareum Holdings Stock Value

Analysts currently give AIM:SAR a rating of Buy.

Buy

Sareum Holdings Company Info

EPS Growth 5Y

9,64%

Market Cap

£0,02 B

Long-Term Debt

£0,00 B

Quarterly earnings

06/10/2026

Dividend

£0,00

Dividend Yield

0,00%

Founded

2004

Industry

Health Care

Country

United Kingdom

Website

Sareum Holdings

ISIN Number

GB00BMC3RJ87

Website

http://www.sareum.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

£0,42

162.5%

Last Update: 04/07/2026

Analysts: 1

Highest Price Target £0,42

Average Price Target £0,42

Lowest Price Target £0,42

In the last five quarters, Sareum Holdings’s Price Target has risen from £1,76 to £1,76 - a 0,00% increase. One analysts predict that Sareum Holdings’s share price will increase in the coming year, reaching £0,42. This would represent an increase of 162,50%.

Top growth stocks in the health care sector (5Y.)

What does Sareum Holdings do?

Sareum Holdings plc a clinical stage small molecule drug development company that engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. Products and Services The company is dedicated to offering a range of products and services within the pharmaceutical and biotechnology sectors. The company's primary product offerings revolve around its proprietary drug candidates, which are designed for the treatment of critical conditions, such as cancer and autoi...

Sareum Holdings plc a clinical stage small molecule drug development company that engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases.

Products and Services

The company is dedicated to offering a range of products and services within the pharmaceutical and biotechnology sectors. The company's primary product offerings revolve around its proprietary drug candidates, which are designed for the treatment of critical conditions, such as cancer and autoimmune diseases.

The company’s lead candidate includes SDC-1801. This drug candidate is under investigation for its efficacy in treating various conditions, and it represents a significant advancement in the therapeutic landscape. The candidate is progressing through clinical trials, and initial results are anticipated in the near future. The ongoing research is oriented towards elucidating the safety and efficacy of SDC-1801, for advancing it to later-stage clinical evaluations.

In addition to its primary drug development efforts, the company engages in research and consulting activities that are focused on drug development. These services leverage internal expertise and scientific knowledge to provide valuable insights and support to external partners, including other biotech firms and academic research institutions.

Geographical Markets

The company primarily operates in the United Kingdom (UK) and international biopharmaceutical market.

Trade Names and Patents

The company has established a portfolio of trade names and intellectual property intended to protect its innovations in drug development. The company’s commitment to intellectual property is underscored by its patent registrations associated with its drug candidates.

The company holds several patents pertinent to its platform technology, primarily encompassing methods and compounds related to protein kinase inhibitors. The details surrounding the patents, including names and expiry dates, are strategically managed to secure ongoing competitive advantages in the marketplace.

Marketing

The company employs a targeted sales and marketing approach focused on engaging strategic partners within the biopharmaceutical industry. The company’s marketing strategy is primarily directed towards strengthening relationships with pharmaceutical companies, research institutions, and healthcare providers.

The marketing efforts include participation in industry conferences and workshops, where the company showcases its research findings and drug candidates. This direct engagement facilitates opportunities for collaboration and enhances visibility within the industry.

Government Regulations

The company operates within a highly regulated environment governed by laws and regulations that dictate every aspect of drug development and commercialization. The company adheres strictly to guidelines set forth by regulatory bodies, such as the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK.

The regulatory framework that governs the company’s operations encompasses requirements for clinical trials, safety assessments, and ethical considerations. The company ensures that its research practices comply with Good Laboratory Practice (GLP) and Good Clinical Practice (GCP) standards, thereby maintaining the integrity and quality of its research outcomes.

History

Sareum Holdings plc was incorporated in 2004.

New support ticket

Explore

Sareum Holdings Stock Value

Sareum Holdings Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Sareum Holdings do?

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

Sareum Holdings Stock Value

Sareum Holdings Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Sareum Holdings do?

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.